ApoE Genotyping and 12-Month Longitudinal Tracking of p-Tau217 Using Fingerstick Collection in a Population-Based Cohort

Q: What biomarkers were assessed in this study?

The study measured ApoE genotype and longitudinal plasma phosphorylated tau at Thr217 (p-tau217) using fingerstick-derived dried plasma spots.

Q: How were participants and samples collected over time?

Participants provided dried plasma spots from on-site fingerstick collection at baseline (V0), 6 months (V6), and 12 months (V12), and paired venipuncture plasma samples were collected at each visit.

Q: What were the key findings regarding fingerstick sampling performance?

p-tau217 levels from capillary dried plasma spots and plasma showed significant correlations across time points, and capillary dried plasma spots had good accuracy to discriminate based on cerebrospinal fluid Aβ status at multiple visits.

Q: What does the conclusion suggest for Alzheimer’s disease management?

The results support fingerstick collection as a reliable, decentralized, temperature-independent approach to quantify p-tau217 longitudinally and genotype ApoE, potentially facilitating patient management.

Sep 30, 2026

Uploaded by Kyle

Background: Implementing recently approved disease-modifying treatments for Alzheimer’s disease requires healthcare systems to adapt quickly. ApoE genotyping and measurement of phosphorylated tau at Thr217 (p-tau217) are essential for correct patient selection and monitoring treatment response. Here, the study evaluated simplified decentralized access using fingerstick sampling for ApoE genotyping and longitudinal plasma p-tau217 quantification from dried plasma spots.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages3

Reading Time8 min

AccessFree to download

Abstract

Background

Method

Result

Conclusion

DOI: 10. 1002/alz70856_106796 BIOMARKERS POSTER PRESENTATION BIOMARKERS (NON-NEUROIMAGING) ApoE Genotyping and 12-Month Longitudinal Tracking of p-Tau217 Using Fingerstick Collection in a Population-Based Cohort Laia Montoliu-Gaya1 Hanna Huber 1 Josep Blazquez2 Luisa Sophie Braun-Wohlfahrt3 Jakub Vávra3 Berta Calm4 Cañada Laia5 Amanda Cano5 Sergi Valero6 Victoria Fernández7 Kaj Blennow8 Henrik Zetterberg8 Mercè Boada9 Nicholas Ashton 10 Xavier Morató Arús6 1 Institute of Neuroscienace and Physiology, University of Gothenburg, Mölndal, Västra Götaland, Sweden 2Ace Alzheimer Center Barcelona, Barcelona, Spain, Spain 3 University of Gothenburg, Gothenburg, Sweden 4Ace Alzheimer Center Barcelona, Barcelona, Spain 5 Research Center and Memory Clinic, Fundació ACE Institut Català de Neurociències Aplicades-Universitat Internacional de Catalunya (UIC), Barcelona, Spain 6Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain 7Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Barcelona, Spain 8 Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Västra Götalands län, Sweden 9 Research Center and Memory Clinic, ACE Alzheimer Center Barcelona, Universitat Internacional de Catalunya, Barcelona, Spain 10 Banner Alzheimer’s Institute, Phoenix, AZ, USA Correspondence Laia Montoliu-Gaya, Institute of Neuroscienace and Physiology, University of Gothenburg, Mölndal, Västra Götaland, Sweden. Email: [laia.montoliu.gaya@gu.se](laia.montoliu.gaya@gu.se) Abstract Background: Implementing recently approved disease-modifying treatments for Alzheimer’s disease (AD) requires healthcare systems to adapt rapidly. ApoE genotyping and determination of phosphorylated tau at Thr217 (p-tau217) levels are essential for accurate patient selection and treatment response monitoring, respectively. Simplified, decentralized access to these biomarkers could reduce patient burden and healthcare resource consumption. Here, we evaluated the performance of fingerstick sampling for ApoE genotyping and longitudinal plasma p-tau217 quantification. Method: Participants were evaluated at the Memory Unit of Ace Alzheimer Center Barcelona and provided longitudinal dried plasma spots (DPS) from on-site fingerstick collection at baseline (V0), 6 months (V6), and 12 months (V12). Capillary DPS cards were shipped to Gothenburg, Sweden, within seven days, without temperature control or cooling, and processed using a custom extraction protocol. Paired venipuncture plasma samples were collected at each visit. p-tau217 levels were measured with the ALZpath Simoa assay. Cerebrospinal fluid (CSF) Aβ1-42/Aβ1-40 measurements were available for all participants. In a sub-cohort, an additional fingerstick sample was collected for ApoE genotyping, performed using real-time PCR. Result: A total of 58 participants (mean age 75.0 years, 61% female, 38% ApoEε4 carriers) were included in the study. The levels of p-tau217 from capillary DPS and plasma samples showed significant correlations at the three time points (all p <0.001). capillary DPSp-tau217 showed high accuracy to discriminate patients based on their CSFAβ status at V0 (AUC=0.83, CI95% 0.76-0.91), V6 (AUC=0.79, CI95% 0.67-0.91) and This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. © 2025 The Alzheimer’s Association. Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer’s Association. Alzheimer’s Dement. 2025;21(Suppl. 2):e106796. [https://doi.org/10.1002/alz70856_106796](https://doi.org/10.1002/alz70856_106796) wi[leyonlinelibrary.com/journal/alz](leyonlinelibrary.com/journal/alz) 1of3 BIOMARKERS V12 (AUC=0. 73, CI95% 0.63-0.82), similar to the paired plasma. Changes in capillary DPS and venous pl

FAQs

What biomarkers were assessed in this study?

The study measured ApoE genotype and longitudinal plasma phosphorylated tau at Thr217 (p-tau217) using fingerstick-derived dried plasma spots.

How were participants and samples collected over time?

Participants provided dried plasma spots from on-site fingerstick collection at baseline (V0), 6 months (V6), and 12 months (V12), and paired venipuncture plasma samples were collected at each visit.

What were the key findings regarding fingerstick sampling performance?

p-tau217 levels from capillary dried plasma spots and plasma showed significant correlations across time points, and capillary dried plasma spots had good accuracy to discriminate based on cerebrospinal fluid Aβ status at multiple visits.

What does the conclusion suggest for Alzheimer’s disease management?

The results support fingerstick collection as a reliable, decentralized, temperature-independent approach to quantify p-tau217 longitudinally and genotype ApoE, potentially facilitating patient management.

Sep 30, 2026

Uploaded by Kyle